* Q4 LOSS PER SHARE $0.11

* SPRING BANK PHARMA - EXPECTS CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL NOT BE SUFFICIENT TO FUND INITIATION OF ANY PHASE 3 TRIAL FOR INARIGIVIR

* SPRING BANK PHARMA - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $50.6 MILLION AS OF DEC 31, 2017, COMPARED TO $25.5 MILLION AS OF DEC 31, 2016 Source text for Eikon: Further company coverage: